NOVOZYMES A/S/S (NVZMY) vs. Cellectis (CLLS) Head to Head Review

NOVOZYMES A/S/S (OTCMKTS:NVZMY) and Cellectis (NASDAQ:CLLS) are both basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Insider & Institutional Ownership

0.2% of NOVOZYMES A/S/S shares are held by institutional investors. Comparatively, 27.6% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares NOVOZYMES A/S/S and Cellectis’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NOVOZYMES A/S/S $2.28 billion 6.11 $511.29 million $1.75 26.79
Cellectis $21.43 million 39.00 -$78.69 million ($1.93) -10.41

NOVOZYMES A/S/S has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than NOVOZYMES A/S/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NOVOZYMES A/S/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Dividends

NOVOZYMES A/S/S pays an annual dividend of $0.50 per share and has a dividend yield of 1.1%. Cellectis does not pay a dividend. NOVOZYMES A/S/S pays out 28.6% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NOVOZYMES A/S/S and Cellectis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NOVOZYMES A/S/S 1 1 2 0 2.25
Cellectis 0 2 3 0 2.60

Cellectis has a consensus price target of $35.25, suggesting a potential upside of 75.46%. Given Cellectis’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than NOVOZYMES A/S/S.

Profitability

This table compares NOVOZYMES A/S/S and Cellectis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NOVOZYMES A/S/S 22.14% 29.64% 16.60%
Cellectis -362.48% -18.63% -16.73%

NOVOZYMES A/S/S Company Profile

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Cellectis Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.